Literature DB >> 31186892

HCV treatment in patients with decompensated liver disease.

Elizabeth C Verna1.   

Abstract

Entities:  

Year:  2017        PMID： 31186892      PMCID： PMC6499224          DOI： 10.1002/cld.663

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  10 in total

1.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.

Authors:  David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton
Journal:  Gastroenterology       Date:  2017-01-11       Impact factor: 22.682

2.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

3.  The dynamic landscape of liver transplant in the era of effective hepatitis C virus therapy.

Authors:  Elizabeth C Verna
Journal:  Hepatology       Date:  2017-02-06       Impact factor: 17.425

Review 4.  Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.

Authors:  C Bunchorntavakul; K Rajender Reddy
Journal:  J Viral Hepat       Date:  2016-03-28       Impact factor: 3.728

5.  Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.

Authors:  Jagpreet Chhatwal; Sumeyye Samur; Brian Kues; Turgay Ayer; Mark S Roberts; Fasiha Kanwal; Chin Hur; Drew Michael S Donnell; Raymond T Chung
Journal:  Hepatology       Date:  2017-01-06       Impact factor: 17.425

6.  Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Authors:  Michael Charlton; Gregory T Everson; Steven L Flamm; Princy Kumar; Charles Landis; Robert S Brown; Michael W Fried; Norah A Terrault; Jacqueline G O'Leary; Hugo E Vargas; Alexander Kuo; Eugene Schiff; Mark S Sulkowski; Richard Gilroy; Kymberly D Watt; Kimberly Brown; Paul Kwo; Surakit Pungpapong; Kevin M Korenblat; Andrew J Muir; Lewis Teperman; Robert J Fontana; Jill Denning; Sarah Arterburn; Hadas Dvory-Sobol; Theo Brandt-Sarif; Phillip S Pang; John G McHutchison; K Rajender Reddy; Nezam Afdhal
Journal:  Gastroenterology       Date:  2015-05-15       Impact factor: 22.682

7.  Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.

Authors:  Fred Poordad; Eugene R Schiff; John M Vierling; Charles Landis; Robert J Fontana; Rong Yang; Fiona McPhee; Eric A Hughes; Stephanie Noviello; Eugene S Swenson
Journal:  Hepatology       Date:  2016-03-07       Impact factor: 17.425

8.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Authors:  Michael P Curry; Jacqueline G O'Leary; Natalie Bzowej; Andrew J Muir; Kevin M Korenblat; Jonathan M Fenkel; K Rajender Reddy; Eric Lawitz; Steven L Flamm; Thomas Schiano; Lewis Teperman; Robert Fontana; Eugene Schiff; Michael Fried; Brian Doehle; Di An; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Robert S Brown; Michael Charlton
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

9.  Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.

Authors:  Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal; Graham R Foster; William L Irving
Journal:  J Hepatol       Date:  2016-07-05       Impact factor: 30.083

10.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

Authors:  Graham R Foster; William L Irving; Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal
Journal:  J Hepatol       Date:  2016-01-30       Impact factor: 30.083
  10 in total
  1 in total

Review 1.  PRO: Patients With Decompensated Cirrhosis Listed for Liver Transplantation Should Be Treated Pretransplant.

Authors:  Tete Ukpong; Parvez Mantry
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-08-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.